A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)
Our study reaffirmed some existing safety information regarding raloxifene while also unveiling novel risk signals. The findings provided crucial insights to enhance the rational use of the drug and inform safety regulatory strategies.
Authors
- Dezhi Yan (ORCID: https://orcid.org/0009-0002-2670-9555)
- Wei Yan (ORCID: https://orcid.org/0000-0001-5059-8694)
- Hao Liu (ORCID: https://orcid.org/0000-0002-1281-5464)
- Jinsong Li (ORCID: https://orcid.org/0000-0003-3456-662X)
- Di Luo
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/14740338.2024.2443960
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00